ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ELDN vs SIGA // NET PROFIT MARGIN

Eledon Pharmaceuticals Inc. (NASDAQ) VS. SIGA Technologies Inc. (NASDAQ) • 15-METRIC TALLY: ELDN 2 — SIGA 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELDN VS. SIGA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ELDN SIGA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 68.60% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 42.70% -77.70 SIGA /roic <GO>
EV/EBITDA & P/E Valuation — 4.8x — TIE /valuation <GO>
Free Cash Flow Yield — 19.03% — TIE /fcf-yield <GO>
Operating Margin — 25.10% — TIE /operating-margins <GO>
Net Profit Margin ACTIVE — 24.60% — TIE /net-margins <GO>
Revenue Growth (YoY) — -31.80% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 8.22 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 6/9 -5.00 SIGA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.0 39.8 +11.20 ELDN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 9.1x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $212.9M $212.0M $947.6K ELDN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ELDN REV SIGA REV ELDN GROSS % SIGA GROSS % ELDN FCF SIGA FCF
FY 2025 $71.0M $94.6M — 68.6% -$62.3M $43.5M
FY 2024 $74.5M $138.7M — 77.4% -$47.3M $48.8M
FY 2023 $120.4M $139.9M — — -$39.5M $94.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELDN // BETA —
SIGA // BETA —